{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:41:52Z","timestamp":1780360912786,"version":"3.54.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Positron emission tomography (PET) using radiolabeled Abs as imaging tracer is called immuno-PET. Immuno-PET can verify therapeutic Ab delivery and can noninvasively quantify global levels of target expression in tumors of living subjects. The interleukin-2 receptor \u03b1 chain (IL-2R\u03b1; CD25) is a promising target for immune therapy and radioimmunotherapy of lymphomas. Immuno-PET could facilitate this approach by visualizing CD25 expression <jats:italic>in vivo<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We prepared <jats:sup>89<\/jats:sup>Zr-anti-CD25 IgG specifically labeled to sulfhydryl moieties by maleimide-deferoxamine conjugation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and Discussion<\/jats:title><jats:p>CD25(+) SUDHL1 human T-cell lymphoma cells showed high anti-human <jats:sup>89<\/jats:sup>Zr-CD25 IgG binding that reached 32-fold of that of CD25(-) human lymphoma cells and was completely blocked by excess unlabeled Ab. In SUDHL1 tumor-bearing nude mice, pharmacokinetic studies demonstrated exponential reductions of whole blood and plasma activity following intravenous <jats:sup>89<\/jats:sup>Zr-anti-CD25 IgG injection, with half-lives of 26.0 and 23.3 h, respectively. SUDHL1 tumor uptake of <jats:sup>89<\/jats:sup>Zr-CD25 IgG was lower per weight in larger tumors, but blood activity did not correlate with tumor size or blood level of human CD25, indicating minimal influence by circulating soluble CD25 protein secreted from the lymphoma cells. <jats:sup>89<\/jats:sup>Zr-CD25 IgG PET allowed high-contrast SUDHL1 lymphoma visualization at five days. Biodistribution studies confirmed high tumor <jats:sup>89<\/jats:sup>Zr-CD25 IgG uptake (8.7 \u00b1 0.9%ID\/g) that was greater than blood (5.2 \u00b1 1.6%ID\/g) and organ uptakes (0.7 to 3.5%ID\/g). Tumor CD25-specific targeting was confirmed by suppression of tumor uptake to 4.3 \u00b1 0.2%ID by excess unlabeled CD25 IgG, as well as by low tumor uptake of <jats:sup>89<\/jats:sup>Zr-labeled IgG2a isotype control Ab (3.6 \u00b1 0.9%ID). Unlike CD25(+) lymphocytes from mouse thymus that showed specific uptake of anti-mouse <jats:sup>89<\/jats:sup>Zr-CD25 IgG, EL4 mouse lymphoma cells had low CD25 expression and showed low uptake. In immunocompetent mice bearing EL4 tumors, anti-mouse <jats:sup>89<\/jats:sup>Zr-CD25 IgG displayed low uptakes in normal organs as well as in the tumor. Furthermore, the biodistribution was not influenced by Ab blocking, indicating that specific uptake in nontumor tissues was minimal. <jats:sup>89<\/jats:sup>Zr-CD25 IgG immuno-PET may thus be useful for imaging of T-cell lymphomas and noninvasive assessment of CD25 expression on target cells <jats:italic>in vivo<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1017132","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T07:30:58Z","timestamp":1671089458000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Cysteine-specific 89Zr-labeled anti-CD25 IgG allows immuno-PET imaging of interleukin-2 receptor-\u03b1 on T cell lymphomas"],"prefix":"10.3389","volume":"13","author":[{"given":"Jin Hee","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Ho","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0708875","article-title":"Monoclonal antibody therapy for b-cell non-hodgkin\u2019s lymphoma","volume":"359","author":"Cheson","year":"2008","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-692566","article-title":"Peripheral T-cell lymphoma, not otherwise specified","volume":"129","author":"Broccoli","year":"2017","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/14712598.2019.1572746","article-title":"Development of new agents for peripheral T-cell lymphoma","volume":"19","author":"Ito","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1179\/1607845412Y.0000000024","article-title":"Clinical features of de novo CD25(+) diffuse large b-cell lymphoma","volume":"18","author":"Muroi","year":"2013","journal-title":"Hematology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.806658","article-title":"Clinical features of de novo CD25-positive follicular lymphoma","volume":"55","author":"Fujiwara","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00139-3","article-title":"Anti-CD25 antibody-drug conjugates: Improving the delivery of death to lymphoma cells","volume":"8","author":"Schmitz","year":"2021","journal-title":"Lancet Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00103-4","article-title":"Camidanlumab tesirine in patients with relapsed or refractory lymphoma: A phase 1, open-label, multicentre, dose-escalation, dose-expansion study","volume":"8","author":"Hamadani","year":"2021","journal-title":"Lancet Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1189","article-title":"Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7\/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma","volume":"24","author":"Zhang","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1189","article-title":"The anti-CD25 monoclonal antibody 7G7\/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia","volume":"66","author":"Zhang","year":"2006","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4757","article-title":"Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7\/B6 and its combination with unmodified anti-tac (daclizumab) directed toward CD25","volume":"108","author":"Zhang","year":"2006","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1421","article-title":"A phase I clinical trial of CHT-25 a 131I-labeled chimeric anti-CD25 antibody showing efficacy in patients with refractory lymphoma","volume":"15","author":"Dancey","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1516107112","article-title":"90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed hodgkin\u2019s lymphoma","volume":"112","author":"Janik","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2019.3298","article-title":"90Y-daclizumab (Anti-CD25), high-dose carmustine, etoposide, cytarabine, and melphalan chemotherapy and autologous hematopoietic stem cell transplant yielded sustained complete remissions in 4 patients with recurrent hodgkin\u2019s lymphoma","volume":"35","author":"Conlon","year":"2020","journal-title":"Clin Trial Cancer Biother Radiopharm"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004981","article-title":"Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2013.12.005","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Nishikawa","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235598","article-title":"The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation","volume":"115","author":"Farinha","year":"2010","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/cancers13040806","article-title":"Tumor heterogeneity: A great barrier in the age of cancer immunotherapy","volume":"13","author":"El-Sayes","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/CCO.0000000000000598","article-title":"Beyond tissue biopsy: A diagnostic framework to address tumor heterogeneity in lung cancer","volume":"32","author":"Voigt","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/biomedicines8090371","article-title":"Positron emission tomography for response evaluation in microenvironment-targeted anti-cancer therapy","volume":"8","author":"Oriuchi","year":"2020","journal-title":"Biomedicines"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1536012118801223","DOI":"10.1177\/1536012118801223","article-title":"Application of immuno-PET in application of immuno-PET in antibody\u2013drug conjugate development","volume":"17","author":"Carmon","year":"2018","journal-title":"Mol Imaging"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2967\/jnumed.108.056887","article-title":"Abs and antimatter. the resurgence of immuno-PET","volume":"50","author":"Wu","year":"2009","journal-title":"J Nucl Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/ijms18010057","article-title":"Immuno-PET for clinical theranostic approaches. international journal of molecular sciences","volume":"18","author":"Bailly","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c00330","article-title":"124I radiolabeled basiliximab for CD25-targeted immuno-PET imaging of activated T cells","volume":"9","author":"Wang","year":"2022","journal-title":"Mol Pharm"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jlcr.3628","article-title":"Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging","volume":"61","author":"Vivier","year":"2018","journal-title":"J Labelled Comp Radiopharm"},{"key":"B25","article-title":"Bifunctional chelates for metal nuclides","volume":"52","author":"Brechbiel","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.7b00325","article-title":"89Zr-immuno-positron emission tomography in oncology: State-of-the-art 89Zr radiochemistry","volume":"28","author":"Heskamp","year":"2017","journal-title":"Bioconjug Chem"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1038\/s41598-021-83496-3","article-title":"89Zr anti-CD44 immuno-PET monitors CD44 expression on splenic myeloid cells and HT29 colon cancer cells","volume":"11","author":"Park","year":"2021","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4906934","DOI":"10.1155\/2022\/4906934","article-title":"Celecoxib-induced modulation of colon cancer CD133 expression occurs through AKT inhibition and is monitored by 89Zr immuno-PET","volume":"2022","author":"Jung","year":"2022","journal-title":"Mol Imaging"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.250720","article-title":"89Zr-labeled anti-PD-L1 antibody PET monitors gemcitabine therapy-induced modulation of tumor PD-L1 expression","volume":"62","author":"Jung","year":"2021","journal-title":"J Nucl Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5916692","DOI":"10.1155\/2022\/5916692","article-title":"89Zr immuno-PET imaging of tumor PD-1 reveals that PMA upregulates lymphoma PD-1 through NF\u03baB and JNK signaling","volume":"2022","author":"Jung","year":"2022","journal-title":"Mol Imaging"},{"key":"B31","article-title":"Improved biodistribution of 125I-labeled anti-tac disulfide-stabilized fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-tac IgG","volume":"57","author":"Kobayashi","year":"1997","journal-title":"Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","article-title":"Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess","volume":"72","author":"Lindmo","year":"1984","journal-title":"J Immunol Methods"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1088","article-title":"Activating fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia","volume":"64","author":"Zhang","year":"2004","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/BF02592278","article-title":"Soluble interleukin-2 receptor in hairy-cell leukemia: A reliable marker of disease","volume":"23","author":"Ambrosetti","year":"1993","journal-title":"Int J Clin Lab Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1309\/AJCP6Q7QMUVGMVMF","article-title":"Analysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in children","volume":"132","author":"Gualco","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2010.12.011","article-title":"In vivo biodistribution and accumulation of 89Zr in mice","volume":"38","author":"Abou","year":"2011","journal-title":"Nucl Med Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.5.2207","article-title":"Different protein kinase c isoenzymes regulate IL-2 receptor expression or IL-2 synthesis in human lymphocytes stimulated via the TcR","volume":"160","author":"Szamel","year":"1998","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(90)90034-W","article-title":"Regulation of stimulus-induced calcium transport pathways in human T (Jurkat) lymphoblasts","volume":"27","author":"Sarkadi","year":"1990","journal-title":"Mol Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1017132\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T07:31:01Z","timestamp":1671089461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1017132\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2022.1017132"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1017132","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]},"article-number":"1017132"}}